Topic: preclinical research
DNAlite Therapeutics gathered $1.5 million in seed money for gene therapies that slip through the mucus typically blocking access to the GI tract.
Merck and HitGen upsized their licensing agreement to a full discovery collaboration, screening DNA-encoded libraries of billions of small molecules.
A startup exited stealth mode to push a new class of drugs that could help regenerate nerve cells’ insulating myelin sheaths in diseases such as MS.
Gilead’s senior director of clinical research, Adrian Ray, has moved to Nimbus Therapeutics to become its senior vice president of discovery biology.
Roche owes its pipeline to the separation of its research and early development units gRED and pRED—and it won’t be consolidating them anytime soon.
XenoGesis and BioAscent plan to integrate their drug discovery offerings.
Gregory Verdine’s FogPharma raised $66 million in series B financing, with hopes to bring its first product to the clinic by the end of next year.
Concept Life Sciences bought Acquila Biomedical for its translational biology capabilities.
California investment firm Frazier Healthcare Partners has gone over its hard cap target of $400 million as it looks to inject cash into early life science work.
The collaborators hope to learn about the role Sigma1 plays in disease and assess the activity of Context’s inhibitors of the protein.